Amine oxidase inhibitors and development of neuroprotective drugs

Current Neuropharmacology

Volumn 2, Issue 2, 2004, Pages 153-168

  Sowa, Bernard N ^a   Todd, Kathryn G ^a   Tanay, Véronique A M I ^a   Holt, Andrew ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amine oxidase; L deprenyl; Monoamino oxidase (MAO); Neuroprotection; Neurorescue; Phenelzine; Phenylethylidenehydrazine; Semicarbazide sensitive amine oxidase (SSAO); Tranylcypromine

Indexed keywords

10 (N METHYL N PROPARGYLAMINOMETHYL)DIBENZO[B,F]OXEPIN; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 FLUOROPHENYLETHYLIDENEHYDRAZINE; ALPHA TOCOPHEROL; AMINE OXIDASE (COPPER CONTAINING); BENSERAZIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA; CLORGYLINE; COCAINE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LAZABEMIDE; LEVODOPA; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; MORPHINE; N (2 HEPTYL) N METHYLPROPARGYLAMINE; N2 ACETYLPHENELZINE; NEUROPROTECTIVE AGENT; PHENELZINE; RASAGILINE; ROLIPRAM; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIGABATRIN;

ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; ASTROCYTE; CLINICAL TRIAL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL INHIBITION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PANIC; PARKINSON DISEASE; REVIEW; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; STRUCTURE ANALYSIS;

EID: 3042819324     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476800     Document Type: Review

References (185)

1. Abu-Raya, S., Blaugrund, E., Trembovler, V., Shilderman-Bloch, E., Shohami, E., Lazarovici, P. (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. Journal of Neuroscience Research, 58, 456-463.
2. Alafuzoff, I., Helisalmi, S., Heinonen, E.H., Reinikainen, K., Hallikainen, M., Soininen, H., Koivisto, K. (2000) Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. European Journal of Clinical Pharmacology, 55, 815-819.
3. Allain, H., Cougnard, J., Neukirch, H.C., French Selegiline Multicentre Trial, M. (1991) Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial. Acta Neurologica Scandinavica, 84 Supplement 136, 73-78.
4. Altar, C.A. (1999) Neurotrophins and depression. Trends in Pharmacological Sciences, 20, 59-61.
5. Ansari, K.S., Yu, P.H., Kruck, T.P., Tatton, W.G. (1993) Rescue of axotomized immature rat-facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. Journal of Neuroscienee, 13, 4042-4053.
6. Archer, J.R., Harrison, D.E. (1996) L-Deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males. Journal of Gerontology Series A-Biological Sciences & Medical Sciences, 51, B448-B453.
7. Atwood, C.S., Scarpa, R.C., Huang, X., Moir, R.D., Jones, W.D., Fairlie, D.P., Tanzi, R.E., Bush, A.I. (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1-42. Journal of Neurochemistry, 75, 1219-1233.
8. Baker, G.B., Wong, J.T.F., Yeung, J.M., Coutts, R.T. (1991) Effects of the antidepressant phenelzine on brain levels of γ-aminobutyric acid (GABA). Journal of Affective Disorders, 21, 207-211.
9. Ballabriga, J., Pellise, A., Ferrer, I. (1997) L-Deprenyl does not reduce damage in global forebrain ischemia in adult gerbils (Meriones ungiculatus). Journal of Neurological Sciences, 148, 1-5.
10. Barrand, M.A., Callingham, B.A. (1982) Monoamine oxidase activities in brown adipose tissue of the rat: some properties and subcellular distribution. Biochemical Pharmacology, 31, 2177-2184.
11. Berry, M.D. (1999) R-2HMP: an orally active agent combining independent antiapoptotic and MAO-B-inhibitory activities. CNS Drug Review, 5, 105-124.
12. Berry, M.D., Boulton, A.A. (2000) Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. Journal of Neuroscience Research, 60, 150-154.
13. Berry, M.D., Boulton, A.A. (2002) Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicology & Teratology, 24, 667-673.
14. Berry, M.D., Juorio, A.V., Paterson, I.A. (1994) Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Progress in Neurobiology, 44, 141-161.
15. Biagini, G., Frasoldati, A., Fuxe, K., Agnati, L.F. (1994) The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochemistry International, 25, 17-22.
16. Biagini, G., Zoli, M., Fuxe, K., Agnati, L.F. (1993) L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. NeuroReport, 4, 955-958.
17. Bodkin, J.A., Kwon, A.E. (2001) Selegiline and other atypical monoamine oxidase inhibitors in depression. Psychiatric Annals, 31, 385-391.
18. Boulton, A.A. (1999) Symptomatic and neuroprotective properties of aliphatic propargylamines. Mechanisms of Ageing and Development, 111, 201-209.
19. Bourin, M., Hascoet, M., Colombel, M.C., Coutts, R.T., Baker, G.B. (2002) Clonidine potentiates the effects of tranylcypromine, phenelzine and derivatives in the forced swimming test in mice. Journal of Psychiatry & Neuroscience, 27, 178-187.
20. Callingham, B.A., Crosbie, A.E., Rous, B.A. (1995) Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Progress in Brain Research, 106, 305-321.
21. Callingham, B.A., Holt, A., Elliott, J. (1991) Properties and functions of the semicarbazide-sensitive amine oxidases. Biochemical Society Transactions, 19, 228-233.
22. Campi, N., Todeschini, G.P., Scarzella, L. (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clinical Therapy, 12, 306-314.
23. Carlile, G.W., Chalmers-Redman, R.M., Tatton, N.A., Pong, A., Borden, K.E., Tatton, W.G. (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Molecular Pharmacology, 57, 2-12.
24. Carlile, G.W., Chalmers-Redman, R.M., Tatton, N.A., Pong, A.B.K.E., Tatton, W.G. (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Molecular Pharmacology, 57, 2-12.
25. Carrillo, M.C., Kitani, K., Kanai, S., Sato, Y., Miyasaka, K., Ivy, G.O. (1994) (-) Deprenyl increases activities of superoxidase and catalase in certain brain regions in old male mice. Life Sciences, 54, 975-981.
26. Cash, D., Beech, J.S., Rayne, R.C., Bath, P.M., Meldrum, B.S., Williams, S.C. (2001) Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain. Brain Research, 905, 91-103.
27. Chiueh, C.C., Huang, S.J., Murphy, D.L. (1994) Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. Journal of Neural Transmission Supplement, 41, 189-196.
28. Cockroft, K.M., Meistrell 3rd, M., Zimmerman, G.A., Risucci, D., Bloom, O., Cerami, A., Tracey, K.J. (1996) Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke, 27, 1393-1398.
29. Cohen, G., Spina, M.B. (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Annals of Neurology, 26, 689-690.
30. De Girolamo, L.A., Hargreaves, A.J., Billett, E.E. (2001) Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. Journal of Neurochemistry, 76, 650-660.
31. Dogan, A., Rao, A.M., Hatcher, J., Rao, V.L., Baskaya, M.K., Dempsey, R.J. (1999) Effects of MDL 72527, a specific inhibitor of polyamine oxidise, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. Journal of Neurochemistry, 72, 765-770.
32. Ebadi, M., Sharma, S., Shavali, S., Refaey, H.E. (2002) Neuroprotective actions of selegiline. Journal of Neuroscience Research, 67, 285-289.
33. Ebadi, M., Srinivasan, S.K., Baxi, M.D. (1996) Oxidative stress and antioxidant therapy in Parkinson's Disease. Progress in Neurobiology, 48, 1-19.
34. El Hadri, K., Moldes, M., Mercier, N., Andreani, M., Pairault, J., Feve, B. (2002) Semicarbazide-sensitive amine oxidase in vascular smooth muscle cells: differentiation-dependent expression and role in glucose uptake. Arteriosclerosis, Thrombosis & Vascular Biology, 22, 89-94.
35. Elizan, T.S., Yahr, M.D., Moros, D.A., Mendoza, M.R., Pang, S., Bodian, C.A. (1989) Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Archives of Neurology, 46, 1275-1279.
36. Elsworth, J.D., Glover, V., Reynolds, G.P., Sandler, M., Lees, A.J., Phuapradit, P. (1978) (-)-Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology. 578, 33-78.
37. Elsworth, J.D., Roth, R.H. (1993) Deprenyl: pharmacological aspects of its clinical effects. Biogenic Amines, 9, 381-394.
38. Enrique-Tarancon, G., Castan, I., Morin, N., Marti, L,., Abella, A., Camps, M., Casamitjana, R., Palacin, M., Testar, X., Degerman, E., Carpene, C., Zorzano, A. (2000) Substrates of semicarbazide-sensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor- substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells. Biochemical Journal, 350, 171-180.
39. Fahn, S., Chouinard, S. (1998) Experience with tranylcypromine in early Parkinson's disease. Journal of Neural Transmission Supplementum, 52, 49-61.
40. Falsaperia, A., Monici, P.P., Oliani, C. (1990) Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clinical Therapy, 12, 376-384.
41. Ferrer, I., Lizcano, J.M., Hernandez, M., Unzeta, M. (2002) Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infacts and leukoencephalopathy. Neuroscience Letters, 321, 21-24.
42. Filip, V., Kolibas, E. (1999) Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak senile dementia of Alzheimer type study group. Journal of Psychiatry & Neuroscience, 24, 234-243.
43. Finberg, J.P., Lamensdorf, I., Weinstock, M., Schwartz, M., Youdim, M.B. (1999) Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Advances in Neurology, 80, 495-499.
44. Finnegan, K.T., Skratt, J.J., Irwin, I., DeLanney, L.E., Langston, J.W. (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. European Journal of Pharmacology, 184, 119-126.
45. Frautschy, S.A., Walicke, P.A., Baird, A. (1991) Localization of basic fibroblast growth factor and its mRNA after CNS injury. Brain Research, 553, 291-299.
46. Gelowitz, D.L., Paterson, I.A. (1999) Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration. Pharmacology Biochemistry and Behavior, 62, 255-262.
47. Gerlach, M., Youdim, M.B., Riederer, P. (1996) Pharmacology of selegiline. Neurology, 47 supplement 3, S137-S145.
48. Gibson, C.J. (1987) Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. European Journal of Pharmacology, 141, 135-138.
49. Globus, M.Y., Busto, R., Dietrich, W.D., Martinez, E., Valdes, I., Ginsberg, M.D. (1988) Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. Journal of Neurochemistry, 51, 1455-1464.
50. Goad, D.L., Davis, C.M., Liem, P., Fuselier, C.C., McCormack, J.R., Olsen, K.M. (1991) Alzheimer's patients with behavior problems. Journal of Clinical Psychiatry, 52, 342-325.
51. Goggi, J., Theofilopoulos, S., Riaz, S.S., Jauniaux, E., Stern, G.M., Bradford, H.F. (2000) The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. NeuroReport, 11, 3937-3941.
52. Goto, J.J., Gralla, E.B., Valentine, J.S., Cabelli, D.E. (1998) Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studied by pulse radiolysis. Journal of Biological Chemistry, 273, 30104-30109.
53. Green, A.R., Hainsworth, A.H., Jackson, D.M. (2000) GABA potentiation: a logical pharmacological approach for the treatment of acute ischemic stroke. Neuropharmacology, 39, 1483-1494.
54. Group, Parkinson Study (1989) DATATOP: A multicenter controlled clinical trial in Early Parkinson's Disease. Archives of Neurology, 46, 1052-1060.
55. Group, Parkinson Study (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine, 321, 1364-1371.
56. Group, Parkinson Study (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. New England Journal of Medicine, 328, 176-183.
57. Heinonen, E.H., Anttila, M.I., Lammintausta, R.A. (1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clinical Pharmacology and Therapeutics, 56, 742-749.
58. Holt, A., Baker, G.B. (1995) Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Progress in Brain Research, 106, 187-197.
59. Hou, J.G., Lin, L.F., Mytilineou, C. (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-1,4-phenylpyridinium. Journal of Neurochemistry, 66, 74-82.
60. Houen, G. (1999) Mammalian Cu-containing amine oxidases (CAOs): new methods of analysis, structural relationships, and possible functions. Acta Pathologica, Microbiologica et Immunologica Scandinavica Supplement, 96, 1-46.
61. Huang, X., Atwood, C.S., Hartshorn, M.A., Multhaup, G., Goldstein, L.E., Scarpa, R.C., Cuajungco, M.P., Gray, D.N., Lim, J., Moir, R.D., Tanzi, R.E., Bush, A.I. (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 38, 7609-7616.
62. Hyman, C., Hofer, Y.A., Barde, M., Juhasz, G.D., Yancopoulos, S.P., Squinto, R.M., Lindsay, R.M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 350, 230-232.
63. Illei, G., Morgan, D.M. (1979) Polyamine oxidase activity in human pregnancy serum. British Journal of Obstetrics & Gynaecology, 86, 878-881.
64. Ishitani, R., Chuang, D.M. (1996) Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proceedings of the National Academy of Sciences of the USA, 93, 9937-9941.
65. Ishitani, R., Sunaga, K., Tanaka, M., Aishita, H., Chuang, D.M. (1997) Overexpression of glyceraldehyde-3-phosphate dehydrogenase is involved in low K+-induced apoptosis but not necrosis of cultured cerebellar granule cells. Molecular Pharmacology, 51, 542-550.
66. Ivanova, S., Batliwalla, F., Mocco, J., Kiss, S., Huang, J., Mack, W., Coon, A., Eaton, J.W., Al-Abed, Y., Gregersen, P.K., Shohami, E., Connolly, E.S., Jr., Tracey, K.J. (2002) Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proceedings of the National Academy of Sciences of the USA, 99, 5579-5584.
67. Ivanova, S., Botchkina, G.I., Meistrell, M., 3rd, Batliwalla, F., Dubinsky, J.M., Iadecola, C., Wang, H., Gregersen, P.K., Eaton, J.W., Tracey, K.J. (1998) Cerebral ischemia enhances polyamine oxidation: Identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. Journal of Experimental Medicine, 188, 327-340.
68. Iwasaki, Y., Ikeda, K., Shiojima, T., Kobayashi, T., Tagaya, N., Kinoshita, M. (1996) Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat. Neurological Research, 18, 168-170.
69. Kafitz, K.W., Rose, C.R., Thoenen, H., Konnerth, A. (1999) Neurotrophin-evoked rapid excitation through TrkB receptors. Nature, 401, 918-921.
70. Kieburtz, K., McDermott, M., Shoulson, I., Fahn, S., Brin, M., Goetz, C., Lang, A., Olanow, C.W. (1996) Effect of lazabemide on the progression of disability in early Parkinson's disease. Annals of Neurology, 40, 99-107.
71. Kitani, K., Kanai, S., Ivy, G.O., Carrillo, M.C. (1999) Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mechanisms of Ageing and Development, 111, 211-221.
72. Knoll, J. (1981) The Pharmacology of selective monoamine oxidase inhibitors in the brain. In: Paykol, E.S., Youdim, M.B.H. Monoamine Oxidase Inhibitors: The State of the Art. New York, N.Y. John Wiley & Sons. pp. 45-61.
73. Knoll, J. (1988) The striatal dopamine dependency of lifespan in male rats. Longevity study with (-) deprenyl. Mechanisms of Aging and Development, 46, 237-262.
74. Kontkanen, O., Castren, E. (1999) Trophic effects of selegiline on cultured dopaminergic neurons. Brain Research, 829, 190-192.
75. Koutsilieri, E., O'Callaghan, J.F., Chen, T.S., Riederer, P., Rausch, W.D. (1994) Selegiline enhances survival and neurite outgrowth of MPP+-treated dopaminergic neurons. European Journal of Pharmacology, 269, R3-R4.
76. Kragten, E., Lalande, I., Zimmermann, K., Roggo, S., Schindler, P., Muller, D., van Oostrum, J., Waldmeier, P., Furst, P. (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. Journal of Biological Chemistry, 273, 5821-5828.
77. Kwan, E., Baker, G.B., Shuaib, A., Ling, L., Todd, K.G. (2001) N-methyl, N-propargyl-2-phenylethylamine (MPPE), an analogue of deprenyl, increases neuronal cell survival in thiamine deficiency encephalopathy. Drug Development Research, 51, 244-252.
78. Langford, S.D., Trent, M.B., Balakumaran, A., Boor, P.J. (1999) Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicology & Applied Pharmacology, 155, 237-244.
79. Leßmann, V. (1998) Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. General Pharmacology, 31, 667-674.
80. Lee, Y., Sayre, L.M. (1998) Reaffirmation that metabolism of polyamines by bovine plasma amine oxidase occurs strictly at the primary amino termini. Journal of Biological Chemistry, 273,
81. Lees, A.J. (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's Disease. British Medical Journal, 311, 1602-1607.
82. LeWitt, P.A. (1993) Neuroprotection by anti-oxidant strategies in Parkinson's Disease. European Journal of Neurology, 33 Supplement 1, 24-30.
83. Li, X.M., Juorio, A.V., Qi, J., Boulton, A.A. (1998) L-Deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. Journal of Neuroscience Research. 53, 235-238.
84. Ling, L., Urichuk, L.J., Sloley, B.D., Coutts, R.T., Baker, G.B., Shan, J.J., Pang, P.K.T. (2001) Synthesis of N-propargylphenelzine and analogues as neuroprotective agents. Bioorganic & Medical Chemistry Letters, 11, 2715-2717.
85. Lippoldt, A., Bandbjer, B., Rosen, L., Richter, E., Ganten, D., Cao, Y., Pettersson, R.F., Fuxe, K. (1993) Photochemically induced focal cerebral ischemia in rat - time dependent and global increase in expression of basic fibroblast growth factor messenger RNA. Brain Research, 625, 45-56.
86. Lyles, G.A. (1996) Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biological, pharmacological and toxicological aspects. International Journal of Biochemistry and Cell Biology, 28, 259-274.
87. Lyles, G.A., Holt, A., Marshall, C.M. (1990) Further studies on the metabolism of methylamine by semicarbazide-sensitive amine oxidase activities in human plasma, umbilical artery and rat aorta. Journal of Pharmacy & Pharmacology, 42, 332-338.
88. Magyar, K., Szende, B., Lengyel, J., Tarczali, J., Sztrmary, I. (1998) The neuroprotective and neuronal rescue effects of (-)-deprenyl. Journal of Neural Transmission Supplementum, 52, 109-123.
89. Magyar, K., Szende, B., Lengyel, J., Tekes, K. (1996) The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. Journal of Neural Transmission Supplement, 48, 29-43.
90. Mangoni, A., Grassi, M.P., Frattola, L., Piolti, R., Bassi, S., Motta, A., Marcone, A., Smirne, S. (1991) Effects of an MAO-B inhibitor in the treatment of Alzheimer Disease. European Neurology, 31,
91. Martignoni, E., Bono, G., Blandini, F., Sinforiani, E., Merlo, P., Nappi, G. (1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type influence of treatment with l deprenyl. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 3, 15-26.
92. Martin, I.L., Bakish, D., Joffe, R. (1994) In: Kennedy, S. H. Ed., Current Advances in Monoamine Oxidase Inhibitor Therapies. Washington D.C., American Psychiatric Press Inc., pp 147-180.
93. Marty, A., Llano, I. (1995) Modulation of inhibitory synapses in the mammalian brain. Current Opinion in Neurobiology. 5, 335-341.
94. Maruyama, W., Akao, Y., Carrillo, M.C., Kitani, K., Youdim, M.B., Naoi, M. (2002) Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicology and Teratology, 24, 675-682.
95. Maruyama, W., Akao, Y., Youdim, M.B., Davis, B.A., Naoi, M. (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. Journal of Neurochemistry, 78, 727-735.
96. Maruyama, W., Takahashi, T., Youdim, M. (2001) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. Journal of Neural Transmission, 109,
97. Maruyama, W., Weinstock, M., Youdim, M.B., Nagai, M., Naoi M. (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neuroscience Letters, 341, 233-236.
98. Matsui, Y., Kumagae, Y. (1991) Monoamine oxidase inhibitors prevent striatal necrosis induced by transient forebrain ischemia. Neuroscience Letters, 126, 175-178.
99. McKenna, K.F., Baker, G.B., Coutts, R.T. (1991) N2-Acetylphenelzine: effects on rat's brain GABA, alanine and biogenic amines. Naunyn-Schmiedebergs Archives of Pharmacology, 343, 478-482.
100. McKenna, K.F., McManus, D.J., Baker, G.B., Coutts, R.T. (1994) Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. Journal of Neural Transmission Supplement, 41, 115-122.
101. Milgram, N.W., Racine, R.J., Nellis, P., Mendonca, A., Ivy, G.O. (1990) Maintenance of l-deprenyl prolongs life in aged male rats. Life Sciences, 47, 415-420.
102. Miura, T., Suzuki, K., Kohata, N., Takeuchi, H. (2000) Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry, 39, 7024-7031.
103. Monteverde, A., Gnemmi P, R.F., Finali, G.C. (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clinical Therapy, 12, 315-322.
104. Murphy, D.L., Garrick, N.A., Aulakh, C.S., Cohen, R.M. (1984) New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. Journal of Clinical Psychiatry, 45, 37-43.
105. Myllyla, V.V., Sotaniemi, K.A., Vuorinen, J.A., Heinonen, E.H. (1991) Selegiline as a primary treatment of Parkinson's disease. Acta Neurological Scandinavica, 84 supplement 136, 70-72.
106. Mytilineou, C., Cohen, G. (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. Journal of Neurochemistry, 45, 1951-1953.
107. Mytilineou, C., Leonardi, E.K., Radcliffe, P., Heinonen, E.H., Han, S.K., Werner, P., Cohen, G., Olanow, C.W. (1998) Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. Journal of Pharmacology and Experimental Therapeutics, 284, 700-706.
108. Mytilineou, C., Radcliffe, P., Leonardi, E.K., Werner, P., Olanow, C.W. (1997) L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. Journal of Neurochemistry, 68, 33-39.
109. Nibuya, M., Morinobu, S., Duman, R.S. (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic ECS and antidepressant drug treatments. Journal of Neuroscience, 15, 7539-7547.
110. Nibuya, M., Nestler, E.J., Duman, R.S. (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Journal of Neuroscience, 16, 2365-2372.
111. Olanow, C.W. (1993) A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's Disease. Movement Disorders, 8 Supplement 1, S1-S7.
112. Olanow, C.W. (1996) Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology, 47 (6 supplement 3), S210-216.
113. Panahi, M., Al-Tiraihi, T. (2002) Morphometric evaluation of the neuroprotective effect of deprenyl on postaxotomic motor neuron losses. Clinical Neuropharmocology, 25, 75-78.
114. Parkinson Study, Group (1989) DATATOP: A Multicenter controlled clinical trial in Early Parkinson's Disease. Archives of Neurology, 46, 1052-1060.
115. Parkinson Study, Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine, 321, 1364-1371.
116. Parkinson Study, Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. New England Journal of Medicine, 328, 176-183.
117. Parkinsonian Study, G. (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch of Neurology, 59, 1937-1943.
118. Paslawski, T., Knaus, E., Iqbal, N., Coutts, R.T., Baker, G.B. (2001) β-Phenylethylidenehydrazine, a novel inhibitor of GABA-transaminase. Drug Development Research, 54, 35-39.
119. Paterson, I.A., Juorio, A.V., Boulton, A.A. (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? Journal of Neurochemistry, 55, 1827-1837.
120. Paterson, I.A., Zhang, D., Warrington, R.C., Boulton, A.A. (1998) R-Deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. Journal of Neurochemistry, 70, 515-523.
121. Perlmutter, L.S., Myers, M.A., Barron, E. (1994) Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microscopy Research & Technique, 28, 204-215.
122. Piccinin, G.L., Finali, G., Piccirilli, M. (1990) Neuropsychological effects of l-deprenyl in Alzheimer's type dementia. Clinical Neuropharmacology, 13, 147-163.
123. Popov, N., Matthies, H. (1969) Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. Journal of Neurochemistry, 16, 899-907.
124. Quitkin, F., Rothschild, R., Stewart, J.W., McGrath, P.J., Harrison, W.M. (1994) In: S. H. Kennedy, Ed., Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington D.C., American Psychiatric Press Inc., pp 184-204.
125. Revuelta, M., Venero, J.L., Machado, A., Cano, J. (1997) Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes. Glia, 21, 204-216.
126. Riggs, J.E. (1997) Deprenyl, excess mortality, and epidemiological traps. Clinical Neuropharmacology, 20, 276-278.
127. Rosenstiel, P., Sievers, J., Lucius, R. (2002) (-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo. Cell & Tissue Research, 308, 167-175.
128. Ruehl, W.W., Entriken, T.L., Muggenburg, B.A., Bruyett, D.S., Griffith, W.G., Hanh, F.F. (1997) Treatment with L-deprenyl prolongs life in elderly dogs. Life Sciences, 61, 1037-1044.
129. Russo-Neustadt, A.A., Beard, R.C., Huang, Y.M., Cotman, C.W. (2000) Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience, 101, 305-312.
130. Salmi, M., Jalkanen, S. (2001) VAP-1: an adhesin and an enzyme. Trends in Immunology, 22, 211-216.
131. Salo, P.T., Tatton, W.G. (1992) Deprenyl reduces the death of motor neurons caused by axotomy. Journal of Neuroscience Research, 31, 394-400.
132. Salonen, T., Haapalinna, A., Heinonen, E., Suhonen, J., Hervonen, A. (1996) Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathologica, 91, 466-474.
133. Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C., Pfeiffer, E., Schneider, L.S., Thal, L.J. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's Disease. New England Journal of Medicine, 336, 1216-1222.
134. Sayre, L.M., Perry, G., Harris, P.L., Liu, Y., Schubert, K.A., Smith, M.A. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. Journal of Neurochemistry, 74, 270-279.
135. Schneider, L.S., Pollock, V.E., Zemansky, M.F., Gleason, R.P., Palmer, R., Sloane, R.B. (1991) A pilot study of low dose L-deprenyl in Alheimer's disease. Journal of Geriatric Psychiatry and Neurology, 4, 143-148.
136. Schwartz-Bloom, R.D., Sah, R. (2001) γ-Aminobutyric acid A neurotransmission and cerebral ischemia. Journal of Neurochemistry, 77, 353-371.
137. Seiler, N. (2000) Oxidation of polyamines and brain injury. Neurochemical Research, 25, 471-490.
138. Seiler, N., Badolo, L., Duranton, B., Vincent, F., Schneider, Y., Gosse, F., Raul, F. (2000) Effect of the polyamine oxidase inactivator MDL 72527 on N1-(n-octanesulfonyl)spermine toxicity. International Journal of Biochemistry & Cell Biology, 32, 1055-1068.
139. Semkova, I., Wolz, P., Schilling, M., Krieglstein, J. (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. European Journal of Pharmacology, 315, 19-30.
140. Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., Barde, A. (1992) Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature, 360, 757-759.
141. Seniuk, N.A., Henderson, J.T., Tatton, W.G., Roder, J.C. (1994) Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R (-)-deprenyl. Journal of Neuroscience Research, 54, 975-981.
142. Shimazu, S., Katsuki, H., Akaike, A. (1999) Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity. European Journal of Pharmacology, 377, 29-34.
143. Shirayama, Y., Chen, A.C.H., Nakagawa, S., Russell, D.S., Duman, R. (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience, 22, 3251-3261.
144. Shuaib, A., Ijaz, S., Hasan, S., Kalra, J. (1992) Gamma-vinyl GABA prevents hippocampal and substantia nigra reticulata damage in repetitive transient forebrain ischemia. Brain Research, 590, 13-17.
145. Shuaib, A., Ijaz, S., Miiyashita, H., Hussain, S., Kanthan, R. (1997) GABA and glutamate levels in the substantia nigra reticulata following repetitive cerebral ischemia in gerbils. Experimental Neurology, 147, 311-315.
146. Shults, C.W., Kimber, T., Marin, D. (1996) Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. NeuroReport, 7, 627-631.
147. Siuciak, J.A., Lewis, D.R., Wiegand, S.J., Lindsay, R.M. (1996) Antidepressant-like effect of brain derived neurotrophic factor. Pharmacology, Biochemistry and Behavior, 56, 131-137.
148. Sivenius, J., Sarasoja, T., Aaltonen, H., Heinonen, E., Kilkku, O., Reinikainen, K. (2001) Selegiline treatment facilitates recovery after stroke. Neurorehabilitation and Neuronal Repair, 15, 183-190.
149. Snowdon, D.A., Greiner, L.H., Markesbery, W.R. (2000) Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Annals of the New York Academy of Sciences, 903, 34-38.
150. Sowa, B.N., Knaus, E.E., Todd, K.G., Davood, A., Baker, G.B. (2003) Biochemical activity of 4-fluorophenylethylidenehydrazine and its potential as a neuroprotectant in cerebral ischemia. Journal of Neurochemistry, 85 supplement 1, 10.
151. Speiser, Z., Mayk, A., Eliash, S., Cohen, S. (1999) Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. Journal of Neural Transmission, 106, 593-606.
152. Sterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., Miskolczi, I., Molnar, S., Rantal, F., Tamas, T., Toth, G., Zagyva, A., Zekany, A., Lavian, G., Gross, A., Friedman, R., Razin, M., Huang, W., Krais, B., Chorev, M., Youdim, M., Weinstock, M. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Journal of Medicinal Chemistry, 45, 5260-5279.
153. Stoll, S., Hafner, U., Kraenzlin, B., Mueller, W.E. (1997) Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiology of Aging, 18, 205-211.
154. Szende, B., Bokonyi, G., Bocsi, J., Keri, G., Timar, F., Magyar, K. (2001) Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. Journal of Neural Transmission, 108, 25-33.
155. Tanay, V.A.-M.I., Todd, K.G., Baker, G.B. (2002) Phenylethylidenehydrazine, a novel GABA-T inhibitor, rescues neurons from cerebral ischemia. Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Montréal, Canada.
156. Tang, Y.P., Ma, Y.L., Chao, C.C., Chen, K.Y., Lee, E.H. (1998) Enhanced glial cell line-derived neurotrophic factor mRNA
157. Tariot, P.N., Sunderland, T., Weingartner, H., Murphy, D.L., Welkowitz, J.A., Thompson, K., Cohen, R.M. (1987) Cognitive effects of l-deprenyl in Alzheimer's Disease. Psychopharmacology, 91, 489-495.
158. Tatton, W.G. (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Movement Disorders, 8 Supplement 1, S20-30.
159. Tatton, W.G., Chalmers-Redman, R.M. (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology, 47, S171-183.
160. Tatton, W.G., Chalmers-Redman, R.M., Elstner, M., Leesch, W., Jagodzinski, F.B., Stupak, D.P., Sugrue, M.M., Tatton, N.A. (2000) Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. Journal of Neural Transmission Supplement, 60, S77-S100.
161. Tatton, W.G., Greenwood, C.E. (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. Journal of Neuroscience Research, 30, 666-672.
162. Teravainen, H. (1990) Selegiline in Parkinson's disease. Acta Neurologica Scandinavica, 81, 333-336.
163. Tetrud, J.W., Langston, J.W. (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science, 245, 519-522.
164. Thiffault, C., Quirion, R., Poirier, J. (1997) The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Molecular Brain Research, 49, 127-136.
165. Todd, K.G., Baker, G.B. (1995) GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. Journal of Affective Disorders, 35, 125-129.
166. Todd, K.G., Banigesh, A.I., Baker, G.B., Coutts, R.T., Shuaib, A. (1999) Phenylethylidenehydrazine, a novel GABA-T inhibitor, has neuroprotective actions in transient global ischemia. Journal of Neurochemistry, 73, S202B.
167. Todd, K.G., Butterworth, R.F. (1998) Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency. Journal of Neuroscience Research, 52, 240-246.
168. Vaidya, V.A., Duman, R.S. (2001) Depression - emerging insights from neurobiology. British Medical Bulletin, 57, 61-79.
169. Vujcic, S., Diegelman, P., Bacchi, C.J., Kramer, D.L., Porter, C.W. (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochemical Journal, 367, 665-675.
170. White, W.H., Gunyuzlu, P.L., Toyn, J.H. (2001) Saccharomyces cerevisiae is capable of de novo pantothenic acid biosynthesis involving a novel pathway of β-alanine production from spermine. Journal of Biological Chemistry, 276, 10794-10800.
171. Wilson, R.S., Mendes De Leon, C.F., Barnes, L.L., Schneider, J.A., Bienias, J.L., Evans, D.A., Bennett, D.A. (2002) Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287, 742-748.
172. Wu, R.M., Chen, R.C., Chiueh, C.C. (2000) Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Annals of the New York Academy of Sciences, 899, 255-261.
173. Wu, R.M., Murphy, D.L., Chiueh, C.C. (1996) Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Annals of the New York Academy of Sciences, 786, 379-390.
174. Xu, L., Ma, J., Seigel, G.M., Ma, J.X. (1999) l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochemical Pharmacology, 58, 1183-1190.
175. Yan, Q., Elliot, J., Snider, W.D. (1992) Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature, 360, 753-755.
176. Youdim, M.B., Weinstock, M. (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mechanisms of Ageing and Development, 123, 1081-1086.
177. Yu, P.H. (2001) Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Medical Hypotheses, 57, 175-179.
178. Yu, P.H., Davis, B.A., Boulton, A.A. (1992) Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. Journal of Medicinal Chemistry, 35, 3705-3713.
179. Yu, P.H., Davis, B.A., Boulton, A.A. (1994) Neuroprotective effects of some monoamine oxidase B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. Journal of Neurochemistry, 63, 1820-1828.
180. Yu, P.H., Wright, S., Fan, E.H., Lun, Z.R., Gubisne-Harberle, D. (2003) Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochimica et Biophysica Acta, 1647, 193-199.
181. Yu, P.H., Zhang, X., Zuo, D.M., Lai, C.T., Tieu, K., Davis, B.A., Boulton, A.A. (1998) Aliphatic N-methylpropargylamines as potential neurorescue agents. Restorative Neurology & Neuroscience, 12, 113-118.
182. Zhang, D. (2001). Anti-apoptotic actions of R-2HMP in cerebellar granule cells: changes of mitochondrial membrane potential and sub-cellular GAPDH protein. Ph.D. Thesis, University of Saskatchewan, Saskatoon.
183. Zhang, F., Casey, R.M., Ross, M.E., Iadecola, C. (1996) Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke, 27, 317-323.
184. Zhang, X., Zuo, D.M., Yu, P.H. (1995) Neuroprotection by R(-)-deprenyl and N-2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin, induced degeneration of noradrenergic neurons in the rat locus coeruleus. Neuroscience Letters, 186, 45-48.
185. Zuo, D.-M., Yu, P.H. (1994) Semicarbazide-sensitive amine oxidase and monoamine oxidase in rat brain microvessels, meninges, retina and eye sclera. Brain Research Bulletin, 33, 307-311.